- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03621020
Clinical Performance Evaluation of T-TAS 01 PL Chip
Study Overview
Status
Intervention / Treatment
Detailed Description
This study will measure primary hemostatic ability using the T-TAS 01 System with PL chip, with a comparison to clinical truth. The study will be conducted at 3 locations in the United States and will enroll approximately 335 subjects. The following subject populations will be enrolled into the study (expected enrollment numbers indicated in parentheses):
- Ostensibly healthy subjects without primary hemostasis abnormalities, e.g. a "healthy platelet" normal control population (N = 150)
- Subjects taking 81+ mg daily aspirin (N = 81)
- Subjects taking dual antiplatelet therapy (N = 51)
- Subjects with von Willebrand disease (vWD; N = 47)
- Subjects with Glanzmann's thrombasthenia (N = 5)
Subjects may be recruited either prospectively or based on their simultaneous participation in other studies involving blood collection, provided that the enrollment criteria. Blood samples will be collected after enrollment and subject participation will be complete after blood samples are collected and all necessary information is collected to complete the case report form (CRF). Blood sample testing with T-TAS 01 will occur locally at each investigational site. Blood sample testing for clinical truth assessment may be tested either locally or remotely, depending on the local availability of the various tests used for determining clinical truth.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
CA
-
Bordeaux, CA, France, 92131
- Centre hospitalier Universitaire de Bordeaux
-
-
-
-
California
-
San Francisco, California, United States, 94112
- San Francisco General Hospital
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
-
Maryland
-
Baltimore, Maryland, United States, 21215
- Sinai Hospital of Baltimore
-
Lutherville, Maryland, United States, 21093
- Inova Cardiology Baltimore
-
-
Virginia
-
Falls Church, Virginia, United States, 22042
- Inova Heart and Vascular Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Normal Controls:
Inclusion Criteria
- Males and females age 21 years or older.
- Able and willing to provide written informed consent. Exclusion Criteria
- Abnormal results from assays used to establish clinical truth (retrospective exclusion).
- Hospitalization or doctor's visits within prior 30 days, except for routine checkup/physical examination.
- Use of antiplatelet therapy within the past 14 days, e.g. aspirin, clopidogrel, prasugrel, ticagrelor, cilostazol.
- Use of anticoagulant drugs within the past 14 days, e.g. heparin, bivalirudin, warfarin, rivaroxaban, and apixaban.
- Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) such as celecoxib, rofecoxib, etc. within the past 14 days.
- History of anemia.
- Known thrombocytopenia (platelet count < 100,000/μL).
- Significant renal dysfunction or dialysis.
- History of platelet disorders e.g. von Willebrand factor deficiency, Glanzmann's thrombasthenia or Bernard-Soulier syndrome.
- History of hemophilia or bleeding disorders.
History of bleeding, with Bleeding Score ≥ 5 (Tosetto J Thromb Haemost 2006). See Appendix A. Scores will be assigned based on health history according to the following categories:
- Epistaxis
- Cutaneous bleeding
- Bleeding from minor wounds
- Bleeding from oral cavity
- Gastrointestinal bleeding
- Bleeding from tooth extraction
- Surgical bleeding
- Menorrhagia
- Post-partum hemorrhage
- Muscle hematoma
- Hemarthrosis
- Central nervous system bleeding
- Females who are in the last trimester of pregnancy, or are breastfeeding.
- Known active gastrointestinal disease including peptic ulcers, gastro-esophageal reflux disease (GERD), and hyperacidity.
- Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis.
- Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals.
Antiplatelet Therapy Subjects:
Inclusion Criteria
- Males and females age 21 years or older.
Continuous daily ingestion of one of the following antiplatelet therapy regimens:
- 81 mg or higher aspirin
- 81 mg or higher aspirin plus 75 mg daily clopidogrel
- 81 mg or higher aspirin plus 10 mg daily prasugrel
- 81 mg aspirin plus 180 mg daily ticagrelor
- Able and willing to provide written informed consent. Exclusion Criteria
- Use of antiplatelet therapy besides aspirin (e.g. clopidogrel, prasugrel, ticagrelor, cilostazol, abciximab, eptifibatide) within the past 14 days.
- Use of anticoagulant drugs within the past 14 days, e.g. heparin, bivalirudin, warfarin, rivaroxaban, and apixaban.
- Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) such as celecoxib, rofecoxib, etc. within the past 14 days.
- Significant renal dysfunction or dialysis.
- Known thrombocytopenia (platelet count < 100,000/μL).
- History of platelet disorders e.g. von Willebrand factor deficiency, Glanzmann thrombasthenia or Bernard-Soulier syndrome.
- History of hemophilia or bleeding disorders.
- Females who are in the last trimester of pregnancy, or are breastfeeding.
- Known active gastrointestinal disease including peptic ulcers, gastro-esophageal reflux disease (GERD), and hyperacidity.
- Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis.
- Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals.
vWD Subjects: Inclusion Criteria
- Males and females age 21 years or older.
- Prior diagnosis of von Willebrand disease type 1, 2A, 2B, 2M, or 3
History of bleeding, with Bleeding Score ≥ 5, which is 99% specific for vWD (Tosetto J Thromb Haemost 2006). See Appendix A. Scores will be assigned based on health history according to the following categories:
- Epistaxis
- Cutaneous bleeding
- Bleeding from minor wounds
- Bleeding from oral cavity
- Gastrointestinal bleeding
- Bleeding from tooth extraction
- Surgical bleeding
- Menorrhagia
- Post-partum hemorrhage
- Muscle hematoma
- Hemarthrosis
- Central nervous system bleeding
- Able and willing to provide written informed consent. Exclusion Criteria
- Prior diagnosis of von Willebrand disease type 2N
- Receiving desmopressin or vWF replacement therapy within the past 2 weeks.
- Use of antiplatelet therapy within the past 14 days.
- Use of anticoagulant drugs within the past 14 days, e.g. heparin, bivalirudin, warfarin, rivaroxaban, and apixaban.
- Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) such as celecoxib, rofecoxib, etc. within the past 14 days.
- Significant renal dysfunction or dialysis.
- Known thrombocytopenia (platelet count < 100,000/μL).
- Females who are in the last trimester of pregnancy, or are breastfeeding.
- Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis.
- Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals.
Glanzmann's Thrombasthenia Subjects:
Inclusion Criteria
- Males and females age 21 years or older.
- Prior diagnosis of Glanzmann's thrombasthenia
- History of bleeding.
- Able and willing to provide written informed consent. Exclusion Criteria
- Use of antiplatelet therapy within the past 14 days.
- Use of anticoagulant drugs within the past 14 days, e.g. heparin, bivalirudin, warfarin, rivaroxaban, and apixaban.
- Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) such as celecoxib, rofecoxib, etc. within the past 14 days.
- Significant renal dysfunction or dialysis.
- Known thrombocytopenia (platelet count < 100,000/μL).
- Females who are in the last trimester of pregnancy, or are breastfeeding.
- Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis.
- Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Healthy controls
Subjects not taking medications with antiplatelet effects, without evidence of vWD or history of congenital platelet abnormalities, without history of significant bleeding.
|
Flow chamber microchip system specific for measuring primary hemostatic ability
System for measuring platelet dysfunction
|
Aspirin monotherapy
Subjects taking 81+ mg daily aspirin and no additional medications with antiplatelet effects, without evidence of vWD or history of congenital platelet abnormalities, without history of significant bleeding.
|
Flow chamber microchip system specific for measuring primary hemostatic ability
System for measuring platelet dysfunction
|
von Willebrand Disease
Subjects diagnosed with vWD (all types except Type 2N), not taking medications with antiplatelet effects, and history of clinically significant bleeding.
|
Flow chamber microchip system specific for measuring primary hemostatic ability
System for measuring platelet dysfunction
|
Glanzmann's Thrombasthenia
Subjects diagnosed with Glanzmann's Thrombasthenia, not taking medications with antiplatelet effects, and history of clinically significant bleeding.
|
Flow chamber microchip system specific for measuring primary hemostatic ability
System for measuring platelet dysfunction
|
Dual antiplatelet therapy (DAPT)
Subjects taking 81 mg daily aspirin and either 75 mg daily clopidogrel, 10 mg daily prasugrel, or 180 mg daily ticagrelor
|
Flow chamber microchip system specific for measuring primary hemostatic ability
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity and specificity for detecting defects in primary hemostasis
Time Frame: Baseline
|
Sensitivity and specificity of the T-TAS 01 PL chip assay against clinical truth
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Jeffrey Dahlen, Ph.D., Hikari Dx, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TQPL-RD-121-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on T-TAS 01 PL Chip
-
Hikari Dx, Inc.Fujimori Kogyo Co., Ltd.Recruiting
-
JIMRO Co., Ltd.Completed
-
920th Hospital of Joint Logistics Support Force...Recruiting
-
Region StockholmSahlgrenska University Hospital, SwedenRecruitingHemostasis in Decompensated Liver Cirrhosis | Inflammation in Decompensated Liver CirrhosisSweden
-
Corregene Biotechnology Co., LtdNot yet recruitingCervical Cancer | Anal Cancer | Head and Neck Cancers | Other Solid Tumors
-
Roswell Park Cancer InstitutePfizerRecruitingAdvanced Malignant Solid Neoplasm | Metastatic Colorectal Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Clinical Stage III... and other conditionsUnited States
-
Tasly Pharmaceutical Group Co., LtdRecruiting
-
Karolinska InstitutetUnknownAttention Deficit Hyperactivity Disorder | Healthy Controls | Emotional Instability Personality Disorder (Borderline Personality Disorder)
-
Corregene Biotechnology Co., LtdRecruitingCervical Cancer | Anal Cancer | Head and Neck CancersChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Not yet recruitingMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colon Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8United States